Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma

Int J Urol. 2023 Aug;30(8):634-647. doi: 10.1111/iju.15208. Epub 2023 Jun 9.

Abstract

Current guidelines recommend endoscopic management (EM) for patients with low-risk upper urinary tract urothelial carcinoma, as well as those with an imperative indication. However, regardless of the tumor risk, radical nephroureterectomy is still mainly performed worldwide despite the benefits of EM, such as renal function maintenance, no hemodialysis requirement, and treatment cost reduction. This might be explained by the association of EM with a high risk of local recurrence and progression. Furthermore, the need for rigorous patient selection and close surveillance following EM may be relevant. Nevertheless, recent developments in diagnostic modalities, pathological evaluation, surgical devices and techniques, and intracavitary regimens have been reported, which may contribute to improved risk stratification and treatments with superior oncological outcomes. In this review, considering recent advances in endourology and oncology, we propose novel treatment strategies for optimal EM.

Keywords: laser ablation; percutaneous surgery; upper urinary tract; ureteroscopic surgery; ureteroscopy; urothelial carcinoma.

Publication types

  • Review

MeSH terms

  • Carcinoma, Transitional Cell* / pathology
  • Humans
  • Kidney Neoplasms* / pathology
  • Kidney Pelvis / pathology
  • Neoplasm Recurrence, Local / pathology
  • Treatment Outcome
  • Ureteral Neoplasms* / pathology
  • Ureteroscopy / methods
  • Urinary Bladder Neoplasms* / pathology